BNGO News and Press, Bionano Genomics Inc. From 01/15/21

Charah Solutions (CHRA) +105% on being awarded large-scale, 12-Year ash marketing contract.DBV Technologies (DBVT) +57% on FDA response regarding Viaskin Peanut application.ObsEva (OBSV) +43%.Atlantic Power (AT) +41% on being acquired by I Squared Capital.Senseonics Holdings (S...

Saphyr can measure large expansions of disease-causing genomic repeats, impossible with other modern techniques, enabling study of a broad range of currently inaccessible genetic diseases Genetic disease cases undiagnosed using existing methods were solved by optical genome ...

Trending Penny Stocks To Watch For The End Of The Week As we inch further into 2021, investors continue to focus on penny stocks . But, if this year has shown us anything, it’s that volatility and speculation are both very high. During this week, several factors have been imp...

Shares of Bionano Genomics (NASDAQ: BNGO) extended their recent gains on Thursday, as the biotechnology company's Next-Generation Cytogenomics Symposium took place. As of 3 p.m. EST today, Bionano's stock price was up more than 38%. Day three of Bionano's symposium saw several d...

Preliminary readout on Saphyr validation study for brain cancer presents path to solid tumor LDT Saphyr outperforms Oncoscan array for structural variation and copy number variation detection in solid tumors Saphyr provides comprehensive and clear picture of structural...

Nasdaq notified Bionano Genomics (BNGO) that it has regained compliance with its minimum bid price requirement for continued listing.Shares trading 4.4% higher after-hours. For further details see: Bionano Genomics regains Nasdaq compliance

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement for continued list...

Global customer consensus on Saphyr’s capability to identify actionable variants in hematological malignancies detected by several cytogenomic methods combined Saphyr identifies additional variants missed by traditional methods that have prognostic and therapeutic val...

SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 33,368,851 shares of its common stock, including 4,352,458 shares sold pursuant to the underwriters’ exercise in...

Announcing the results and experiences of six users of using its Saphyr® system for optical genome mapping (“OGM”) Bionano Genomics (BNGO) said that the research use only platform has demonstrated 100% concordance with standard methods.Featured in day one of Bionano&#x...